Scientists Develop Next-Gen Antibodies That Boost the Body’s Cancer Killing Cells

Scientists at Southampton University have created new antibodies that supercharge the immune system’s ability to identify and kill cancer cells. This approach involved clustering immune receptors in the body so that stronger signals can be sent out to the specialized cells responsible for zeroing in and killing cancer cells. 

Published in the Nature Communications journal, the study documents how this new approach introduces four-pronged antibody cells instead of the two-pronged ones that naturally exist in our bodies. By converting these antibodies into four-pronged ones, the new cells are better able to bind to more receptors in the body so that a more powerful signal is sent to T cells to attack any cancer cells within the body. 

Under normal circumstances, the body produces ligands in response to a cancer infection. However, the existing Y-shaped antibodies in the body latch to just a pair of ligands, causing the resultant call/signal for an immune system response to be weak. As a result, the T-cell response is also weak. The new four-pronged antibodies attach to more ligands (four in total, with each arm of the new antibody attaching to a ligand) and trigger a stronger response from the immune system, boosting the fight against the cancer that has invaded the body. 

Prof. Aymen Al Shamkhani, the study’s lead author, explains that they sought to leverage existing knowledge about the way in which natural CD27 signaling happens in the body so that the door to excellent medicines can be opened. Their designed antibodies proved, in human cell tests and mouse tests, that doubling the ligands to which antibodies bind strengthened T-cell response to cancer invasions. 

The researchers hope that the new approach they have initiated can make it possible for immune therapies that are more effective against cancer to be developed and commercialized. By helping the immune system to reach its full potential in the anti-cancer fight, a lot more people could have tumor growth suppressed and possibly reversed. 

By using this new approach to enable antibodies to attach to double the two ligands that existing antibodies normally attach to, and by recruiting CD27 receptors to keep the antibody clump held together, the body’s immune system gets primed to launch a stronger attack against cancer, boosting effectiveness rates. This work adds onto what other teams at Calidi Biotherapeutics Inc. (NYSE American: CLDI) and others are doing to advance immunotherapy against cancer to a whole new level that could bring this therapy to more people afflicted by different malignancies. 

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN